<SEC-DOCUMENT>0001193805-19-000412.txt : 20190423
<SEC-HEADER>0001193805-19-000412.hdr.sgml : 20190423
<ACCEPTANCE-DATETIME>20190423162955
ACCESSION NUMBER:		0001193805-19-000412
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190412
FILED AS OF DATE:		20190423
DATE AS OF CHANGE:		20190423

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Fund N.V.
		CENTRAL INDEX KEY:			0001774671
		STATE OF INCORPORATION:			C9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		19761834

	BUSINESS ADDRESS:	
		STREET 1:		GROOT BEGIJNHOF 60/001
		CITY:			LEUVEN
		STATE:			C9
		ZIP:			3000
		BUSINESS PHONE:		32 477750803

	MAIL ADDRESS:	
		STREET 1:		GROOT BEGIJNHOF 60/001
		CITY:			LEUVEN
		STATE:			C9
		ZIP:			3000

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		AM KLOPFERSPITZ 19
		CITY:			MARTINSRIED
		STATE:			2M
		ZIP:			82152
		BUSINESS PHONE:		49 89 250079460

	MAIL ADDRESS:	
		STREET 1:		AM KLOPFERSPITZ 19
		CITY:			MARTINSRIED
		STATE:			2M
		ZIP:			82152

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>e618386_3-fund.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2019-04-12</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001280776</issuerCik>
        <issuerName>IMMUNIC, INC.</issuerName>
        <issuerTradingSymbol>IMUX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001774671</rptOwnerCik>
            <rptOwnerName>Fund N.V.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>GROOT BEGIJNHOF 60/001</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>LEUVEN</rptOwnerCity>
            <rptOwnerState>C9</rptOwnerState>
            <rptOwnerZipCode>3000</rptOwnerZipCode>
            <rptOwnerStateDescription>BELGIUM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1371494</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <remarks>On April 12, 2019, pursuant to an Exchange Agreement, dated as of January 6, 2019, between the Issuer (then known as Vital Therapies, Inc.), Immunic AG (&quot;Immunic&quot;), and the shareholders of Immunic party thereto (the &quot;Exchange Agreement&quot;), the holders of Immunic ordinary shares exchanged all of their outstanding shares for shares of Issuer common stock, resulting in Immunic becoming a wholly-owned subsidiary of the Issuer (the &quot;Transaction&quot;). Immediately following the Transaction, the Issuer changed its name to &quot;Immunic, Inc.&quot; In connection with the Transaction, the Reporting Person received shares of common stock of the Issuer.</remarks>

    <ownerSignature>
        <signatureName>/s/ Michael Singer, Attorney-in-Fact</signatureName>
        <signatureDate>2019-04-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
